Last reviewed · How we verify
NCT04407546
Role of Children in Transmission of COVID-19 to Immunocompromised Patients
trial in Immunosuppression in 109 participants. Terminated before completion.
13 March 2023
Quick facts
| Lead sponsor | Jonsson Comprehensive Cancer Center |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 109 |
| Start date | 27 May 2020 |
| Primary completion | 13 March 2023 |
| Estimated completion | 13 March 2023 |
| Sites | 1 location across United States |
Conditions studied
- Immunosuppression — all drugs for Immunosuppression →
Sponsor
Jonsson Comprehensive Cancer Center — full company profile →
Who can join
Eligibility, any sex, with Immunosuppression. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a study of immunosuppressed individuals living in households with and without children to assess the role of household contact with children in the transmission of SARSCoV-2 to immunocompromised individuals. Through careful collection of epidemiological data in combination with biological specimens, risk factors for SARS-CoV-2 in immunocompromised individuals will be identified. During the initial visits, informed consent will be obtained and consented participants will complete an initial questionnaire and provide biological specimens including nasal swabs, saliva and blood. Thereafter, participants will complete at-home saliva collections and questionnaires on a weekly basis for 6 months. If our research-use only SARS-CoV-2 test is positive, participants will be referred immediately for medical attention and will be followed every 3 days with nasal swabs and saliva samples and weekly blood specimens and optional rectal swabs or fresh stool collection. Additionally, participants will be contacted by telephone at 1 year for follow-up.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04407546
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Immunosuppression
Currently open trials in the same condition.
- NCT07479511 — Adaptation of Lung Transplant Recipients at Extreme Altitude · active not recruiting
- NCT07206277 — Fibroscan to Guide Post Transplant Immunosuppression Minimization · NA · recruiting
- NCT06701825 — Effectiveness and Cost-effectiveness of a Pre-emptive Genotyping Strategy in Patients Receiving Tacrolimus · Phase 4 · recruiting
- NCT06354179 — Evaluation of the Benefits of Administering Immunosuppressive Drugs as Single Daily Doses Over the First Year After Live · Phase 4 · recruiting
- NCT05814432 — Efficacy and Safety of High-dose Liposomal Amphotericin B for Disseminated Histoplasmosis in AIDS · Phase 3 · recruiting
Other Jonsson Comprehensive Cancer Center trials
Trials by the same sponsor.
- NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
- NCT06448286 — PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glio · Phase 3 · not yet recruiting
- NCT07517211 — A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer, · not yet recruiting
- NCT07191717 — Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Resi · Phase 2 · not yet recruiting
- NCT07468903 — Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04407546 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jonsson Comprehensive Cancer Center
- Last refreshed: 24 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04407546.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing